Spero Therapeutics, a clinical-stage biopharmaceutical company, will announce its financial results for the first quarter ending March 31, 2026, on May 13 after market close. The company will also provide a business update but will not hold a conference call. This report follows their recent activities including the resubmission of a New Drug Application for tebipenem HBr to the FDA. Investors should watch for insights on the company's progress in developing treatments for rare and high-need diseases.
LEPAS, a mid-to-premium NEV brand under Chery Auto, has introduced the LEPAS L8 PHEV globally, showcasing advanced hybrid technology, smart driving features, and refined design inspired by the agility and resilience of a leopard. The vehicle offers a...
LEPAS, a mid-to-premium NEV brand under Chery Auto, introduced the LEPAS L8 PHEV globally, featuring advanced hybrid technology, elegant design inspired by the agility and strength of a leopard, and smart driving aids. The vehicle offers a leading th...
Chery Auto's NEV brand LEPAS has introduced the LEPAS L8 PHEV globally, combining advanced hybrid technology with intelligent driving features and sophisticated design. Inspired by the precision and resilience of top athletes, the vehicle features a ...
LEPAS, a premium NEV brand under Chery Auto, has introduced the LEPAS L8 PHEV globally, blending elegant design inspired by a leopard's agility with advanced hybrid technology. The vehicle features a highly efficient LEPAS Super Hybrid system with a ...
Chery Auto's LEPAS brand has introduced the L8 PHEV, a mid-to-premium plug-in hybrid vehicle, to the global market. The car features advanced hybrid technology with a 45.79% efficient engine and a 97.6% efficient transmission, delivering ultra-low fu...
